Latest News and Press Releases

Brian Van Tine, M.D., of Washington University School of Medicine to share data from the ongoing Phase 1/2 study at leading international sarcoma meeting SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct....

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4...

SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, announced that...

Data from the Phase 1 dose escalation portion of the Phase 1/2 KB-0742 study will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October...

SAN MATERO, Calif. and CAMBRIDGE, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...

SAN MATEO, Calif. and CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...

Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML...

SAN MATEO, Calif. and CAMBRIDGE, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...

Katherine Vega Stultz appointed to Board Current Board member Otello Stampacchia, Ph.D., stepped down SAN MATEO, Calif. and CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc....